Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma

European Journal of Surgical Oncology

Volumn 33, Issue 3, 2007, Pages 294-300

  Mylona, E ^a   Alexandrou, P ^a   Mpakali, A ^a   Giannopoulou, I ^a   Liapis, G ^a   Markaki, S ^b   Keramopoulos, A ^b   Nakopoulou, L ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

Author keywords

Breast cancer; Immunohistochemistry; Proliferation; VEGF C; VEGF D; VEGFR 3

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); KI 67 ANTIGEN; PARAFFIN; PROTEIN P53; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CELL MEMBRANE; CELL NUCLEUS; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 34047185818     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.10.015     Document Type: Article

References (42)

1. Costa C., Soares R., and Schmitt F. Angiogenesis: now and then. APMIS 112 (2004) 402-412
2. Stacker S.A., Baldwin M.E., and Achen M.G. The role of tumor lymphangiogenesis in metastatic spread. FASEB J 16 (2002) 922-934
3. McColl B.K., Stacker S.A., and Achen M.G. Molecular regulation of the VEGF family-inducers of angiogenesis and lymphangiogenesis. APMIS 112 (2004) 463-480
4. Joukov V., Sorsa T., Kumar V., et al. Proteolytic processing regulates specificity and activity of VEGF-C. EMBO J 16 (1997) 3898-3911
5. Achen M.G., Jeitsch M., Kukk E., et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinase VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95 (1998) 548-553
6. Veikkola T., Jussila L., Makinen T., et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 20 (2001) 223-1231
7. Karkkainen M.J., Haiko P., Sainio K., et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 5 (2004) 74-80
8. Joukov V., Pajusola K., Kaipainen A., et al. A novel vascular endothelial growth factor, VEGF-C is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15 (1996) 1751-1756
9. Kaipainen A., Korhonen J., Mustonen T., et al. Expression of the fms-like tyrosine kinase. A gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 92 (1995) 3566-3570
10. Stacker S.A., Stenvers K., Caesar C., et al. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem 274 (1999) 32127-32136
11. Witte D., Thomas A., Ali N., Carlson N., and Younes M. Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res 22 (2000) 1463-1466
12. Skobe M., Hawighorst T., Jackson D.G., et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7 (2001) 192-198
13. Stacker S.A., Caesar C., Baldwin M.E., et al. VEGF-D promotes the metastatic spread of tumour cells via the lymphatics. Nat Med 7 (2001) 186-191
14. Yokoyama Y., Charnock-Jones D.S., Licence D., et al. Expression of Vascular Endothelial Growth Factor (VEGF)-D and its Receptor, VEGF Receptor 3, as a prognostic factor in endometrial carcinoma. Clin Cancer Res 3 (2003) 1361-1369
15. Tanigaki Y., Nagashima Y., Kitamura Y., Matsuda H., Mikami Y., and Tsukuda M. The expression of vascular endothelial growth factor-A and -C and receptors 1 and 3: correlation with lymph node metastasis and prognosis in tongue squamous cell carcinoma. Int J Mol Med 4 (2004) 389-395
16. Onogawa S., Kitsadai Y., Tanaka S., Kuwai T., Kimura S., and Chayama K. Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci 95 (2004) 32-39
17. Kitadai Y., Amioka T., Haruma K., et al. Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human oesophageal squamous cell carcinomas. Int J Cancer 93 (2001) 662-666
18. Kurahara H., Takao S., Maemura K., Shinchi H., Natsugoe S., and Aikou T. Impact of vascular endothelial growth factor -C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis. Clin Cancer Res 10 (2004) 8413-8420
19. Ichikura T., Tomimatsu S., Ohkura E., and Mochizuki H. Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma. J Surg Oncol 78 (2001) 132-137
20. Nakamura Y., Yasuoka H., Tsujimoto M., et al. Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow up. Clin Cancer Res 9 (2003) 716-721
21. Nakamura Y., Yasuoka H., Tsujimoto M., et al. Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up. Mod Pathol 16 (2003) 309-314
22. Kinoshita J., Kitamura K., Kabashima A., Saeki H., Tanaka S., and Sugimachi K. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Br Cancer Res Treat 66 (2001) 159-164
23. Okada K., Osaki M., Araki K., Ishiguro K., Ito H., and Ohgi S. Expression of Hypoxia-inducible factor (HIF-1a), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas. Anticancer Res 25 (2005) 3003-3010
24. Gunningham S.P., Currie M.J., Han C., et al. The short form of the alternatively spliced Flt4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers. Clin Cancer Res 6 (2000) 4278-4286
25. Currie M.J., Hanrahan V., Gunningham S.P., et al. Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1a) and the HIF-1a target gene DEC1, but not lymph node metastasis in primary human breast carcinomas. J Clin Pathol 57 (2004) 829-834
26. Yang W., Klos K., Yang Y., Smith T.L., Shi D., and Yu D. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C and D in human breast carcinoma. Cancer 94 (2002) 2855-2861
27. Tavassaoeli F.A., and Davilee P. Tumors of the breast and female genital organs IARC WHO. Classification of tumours No 4 (2003)
28. Robins P., Pinder S., and de Klerk N. Histological grading of breast carcinomas: a study of interobserved agreement. Human Pathol 28 (1995) 873-879
29. Union International Contre Cancer. TNM Classification of International Union against Cancer. In: Hermanek P., and Sabin H. (Eds). TNM Atlas. 4th ed (1992), Springer-Verlag, Berlin 3rd revision
30. Nakopoulou L., Stefanaki K., Panayotopoulou E., et al. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: Correlation with proliferation. Hum Pathol 33 (2002) 863-870
31. McCleilland R.A., Wilson D., Leake R., Finlay P., and Nicholson R.I. A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. Eur J Cancer 27 (1991) 711-716
32. Nakopoulou L., Lazaris A.C., Kavantzas N., et al. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology 68 (2000) 137-143
33. Stacker S.A., Williams R.A., and Achen M.G. Lymphangiogenic growth factors as markers of tumour metastasis. APMIS 112 (2004) 539-549
34. Arinaga M., Noguchi T., Takeno S., Chujo M., Miura T., and Uchida Y. Clinical significance of vascular endothelial growth factor receptor 3 in patients with non-small cell lung carcinoma. Cancer 97 (2003) 457-464
35. Wulfing P., Kersting C., Buerger H., et al. Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br J Cancer 92 (2005) 1720-1728
36. Bairey O., Boycov D., Kaganovsky E., Zimra Y., Shaklai M., and Rabizadeh E. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lympocytic leukaemia (CLL) cells. Leukemia Res 28 (2004) 243-248
37. Akahane M., Akahane T., Shah A., Okajima E., and Thorgeirsson U.P. A potential role for Vascular Endothelial Growth Factor-D as an autocrine growth factor for human breast carcinoma cells. Anticancer Res 25 (2005) 701-708
38. Alam A., Herault J.P., Barron P., et al. Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity. Biochem Biophys Res Commun 324 (2004) 909-915
39. Feng Y., Venema V.J., Venema R.C., Tsai N., and Caldwell R.B. VEGF induces nuclear translocation of Flk-1/KDR, endothelial nitric oxide synthase and caveolin-1 in vascular endothelial cells. Biochem Biophys Res Commun 256 (1999) 192-197
40. Stewart M., Turley H., Cook N., et al. The angiogenic receptor KDR is widely distributed to human tissues and tumors and relocates intracellural on phosphorylation. An immunohistochemical study. Histopathology 43 (2003) 33-39
41. Vacca A., Ria R., Ribatti D., et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 88 (2003) 176-185
42. Neufeld G., Kessler O., and Herzog Y. The interaction of neuropilin-1 and neuropilin-2 with tyrosine-kinase receptors for VEGF. Adv Exp Med Biol 515 (2002) 81-90